Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue mAbs Année : 2015

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B

Résumé

Botulinum neurotoxins (BoNTs) are responsible for human botulism, a life-threatening disease characterized by flaccid muscle paralysis that occurs naturally by food poisoning or colonization of the gastrointestinal tract by BoNT-producing clostridia. BoNTs have been classified as category A agents by the Centers for Disease Control and Prevention. To date, 7 subtypes of BoNT/B were identified showing that subtypes B1 (16 strains) and B2 (32 strains) constitute the vast majority of BoNT/B strains. Neutralizing antibodies are required for the development of anti-botulism drugs to deal with the potential risk. In this study, macaques (Macaca fascicularis) were immunized with recombinant light chain (LC) or heavy chain (HC) of BoNT/B2, followed by the construction of 2 hyper-immune phage display libraries. The best single-chain variable fragments (scFvs) isolated from each library were selected according to their affinities and cross reactivity with BoNT/B1 toxin subtype. These scFvs against LC and HC were further analyzed by assessing the inhibition of in vitro endopeptidase activity of BoNT/B1 and B2 and neutralization of BoNT/B1 and B2 toxin-induced paralysis in the mouse ex vivo phrenic nerve assay. The antibodies B2-7 (against HC) and BLC3 (against LC) were produced as scFv-Fc, and, when tested individually, neutralized BoNT/B1 and BoNT/B2 in a mouse ex vivo phrenic nerve assay. Whereas only scFv-Fc BLC3 alone protected mice against BoNT/B2-induced paralysis in vivo, when B2-7 and BLC3 were combined they exhibited potent synergistic protection. The present study provided an opportunity to assess the extent of antibody-mediated neutralization of BoNT/B1 and BoNT/B2 subtypes in ex vivo and in vitro assays, and to confirm the benefit of the synergistic effect of antibodies targeting the 2 distinct functional domains of the toxin in vivo. Notably, the framework regions of the most promising antibodies (B2-7 and BLC3) are close to the human germline sequences, which suggest that they may be well tolerated in potential clinical development.
Fichier principal
Vignette du fichier
Development of human like scFv Fc antibodies neutralizing Botulinum toxin serotype B.pdf (1022.95 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

pasteur-01783494 , version 1 (02-05-2018)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Christine Rasetti-Escargueil, Arnaud Avril, Siham Chahboun, Rob Tierney, Nicola Bak, et al.. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. mAbs, 2015, 7 (6), pp.1161 - 1177. ⟨10.1080/19420862.2015.1082016⟩. ⟨pasteur-01783494⟩

Collections

PASTEUR
151 Consultations
205 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More